Amerikanische Gesellschaft für Hirudotherapie

Intelligente Bibliothek

Facettierte Suche über alle 5 Register. Filtern nach Registertyp, Evidenzlevel oder Sicherheitsdomäne.

Curated knowledge libraryReference collection

Compounds

114

Hirudin

The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.

Preclinical / mechanisticIn vitro

Calin

Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.

Preclinical / mechanisticIn vitro

Saratin

Anti-platelet adhesion protein blocking collagen-mediated platelet activation.

Preclinical / mechanisticIn vitro

Destabilase

Lysozyme with isopeptidase activity that dissolves stabilized fibrin clots — including aged thrombi resistant to tPA.

Preclinical / mechanisticIn vitro

Hirustasin

Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.

Preclinical / mechanisticIn vitro

Eglin C

Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.

Preclinical / mechanisticIn vitro

Bdellin B3

Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.

Preclinical / mechanisticIn vitro

Antistasin

Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).

Preclinical / mechanisticIn vitro

Decorsin

RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.

Preclinical / mechanisticIn vitro

Ornatin

RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.

Preclinical / mechanisticIn vitro

Theromacin

Antimicrobial peptide active against Gram-negative bacteria — innate immunity of leech.

Preclinical / mechanisticIn vitro

Theromyzin

Antimicrobial peptide; structural analogue of mammalian defensin family.

Preclinical / mechanisticIn vitro

Hementerin

Direct fibrinogenolytic enzyme — degrades fibrinogen independently of plasmin.

Preclinical / mechanisticIn vitro

Lefaxin

Factor Xa inhibitor with anti-inflammatory properties.

Preclinical / mechanisticIn vitro

LDTI (Leech-Derived Tryptase Inhibitor)

Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.

Preclinical / mechanisticIn vitro

Hirudin-PA

Hirudin variant from Hirudinaria manillensis with distinct kinetics.

Preclinical / mechanisticIn vitro

Hirullin P18

Synthetic hirudin variant with improved oral pharmacokinetics — preclinical anticoagulant.

Preclinical / mechanisticIn vitro

LCI (Leech Carboxypeptidase Inhibitor)

Inhibitor of TAFI (thrombin-activatable fibrinolysis inhibitor) — synergizes with hirudin's anticoagulant action.

Preclinical / mechanisticIn vitro

Hementin

Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.

Preclinical / mechanisticIn vitro

Antithrombin III binding protein

Leech-derived inhibitor that potentiates host antithrombin III activity — synergistic anticoagulation.

Preclinical / mechanisticIn vitro

Guamerin

Selective elastase inhibitor from Korean leech — anti-inflammatory potential in COPD and emphysema research.

Preclinical / mechanisticIn vitro

Piguamerin

Plasma kallikrein and trypsin inhibitor from Korean leech — anti-inflammatory and antithrombotic research.

Preclinical / mechanisticIn vitro

Therostasin

Factor Xa inhibitor from Theromyzon tessulatum — Kunitz-domain analog with novel selectivity profile.

Preclinical / mechanisticIn vitro

Haemadin

Picomolar-affinity thrombin inhibitor from Indian buffalo leech — distinct mechanism from hirudin.

Preclinical / mechanisticIn vitro

Macrostomin

Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.

Preclinical / mechanisticIn vitro

Hirunipins

Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.

Preclinical / mechanisticIn vitro

Bdellastasin

Trypsin and plasmin inhibitor; closely related to bdellins — anti-fibrinolytic modulation.

Preclinical / mechanisticIn vitro

Tridegin

Factor XIIIa inhibitor — blocks fibrin cross-linking; novel mechanism distinct from hirudin.

Preclinical / mechanisticIn vitro

Leech C1 Inhibitor (LCi)

Complement system modulator targeting C1q activation — immunological homeostasis.

Preclinical / mechanisticIn vitro

Bdellin A

Trypsin-plasmin inhibitor of Kazal-type family — sister to Bdellin B3.

Preclinical / mechanisticIn vitro

Bdellin B1

Plasmin inhibitor of Kazal-type family — anti-fibrinolytic.

Preclinical / mechanisticIn vitro

Destabilase Isopeptidase Activity

Isopeptidase domain of destabilase that cleaves cross-linked fibrin — distinct from lysozyme domain.

Preclinical / mechanisticIn vitro

Destabilase Lysozyme Activity

Lysozyme domain of destabilase — antimicrobial activity against peptidoglycan-containing bacteria.

Preclinical / mechanisticIn vitro

Antibacterial protein from Asian medicinal leech

Anti-Gram-positive peptide isolated from Asian medicinal leech salivary glands.

Preclinical / mechanisticIn vitro

Leech Ecotin-like Factor

Trypsin and Factor Xa inhibitor with broad-spectrum serine protease activity.

Preclinical / mechanisticIn vitro

Saratin-2

Isoform of saratin — collagen-binding anti-platelet protein from Hirudo medicinalis.

Preclinical / mechanisticIn vitro

Hementin-Like Protein (HLP-1)

Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.

Preclinical / mechanisticIn vitro

LAPP-2 (Leech Anti-Platelet Protein, Isoform 2)

Isoform of LAPP — collagen-binding inhibitor of platelet adhesion.

Preclinical / mechanisticIn vitro

Leech Adhesion-Inhibitor Protein

Salivary protein blocking platelet adhesion to extracellular matrix components.

Preclinical / mechanisticIn vitro

Bdellin C

Additional bdellin variant — Kazal-type proteinase inhibitor with trypsin/plasmin specificity.

Preclinical / mechanisticIn vitro

LDTI-2 (Leech-Derived Trypsin Inhibitor, Variant 2)

Sequence variant of LDTI — selective tryptase / trypsin inhibitor relevant to mast-cell pathways.

Preclinical / mechanisticIn vitro

Leech Pancreatic-Type Trypsin Inhibitor

Leech homolog of pancreatic (Kunitz-type) trypsin inhibitor — broad serine protease inhibition.

Preclinical / mechanisticIn vitro

Leech Elastase Inhibitor

Salivary inhibitor of neutrophil elastase — modulates inflammatory tissue damage.

Preclinical / mechanisticIn vitro

Theromycin-2

Isoform of theromycin — leech-derived antimicrobial / anti-inflammatory peptide.

Preclinical / mechanisticIn vitro

Leech Defensin

Defensin-family cationic antimicrobial peptide identified in leech salivary tissue.

Preclinical / mechanisticIn vitro

Leech Cecropin

Cecropin-homolog antimicrobial peptide identified in the leech salivary secretome.

Preclinical / mechanisticIn vitro

Theromin

Non-hirudin thrombin inhibitor from the rhynchobdellid leech Theromyzon tessulatum — highest-affinity natural inhibitor identified in a non-Hirudo species.

Preclinical / mechanisticIn vitro

Saratin-3

Collagen-binding antiplatelet variant from the Hirudo medicinalis sialotranscriptome — paralog of saratin and saratin-2.

Preclinical / mechanisticIn vitro

Hirudonin

Small thrombin-inhibitor peptide identified in the Hirudo medicinalis salivary transcriptome — truncated hirudin-family analog.

Preclinical / mechanisticIn vitro

Gelin

Antiplatelet peptide identified in leech salivary transcriptome — inhibits platelet aggregation in vitro.

Preclinical / mechanisticIn vitro

Showing first 50 of 114. Refine filters to narrow results.

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Smart Library — Faceted Search Across All Registries | ASH | Amerikanische Gesellschaft für Hirudotherapie